# TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

> **NCT02874404** · PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 13 (actual)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** PI3K-delta Inhibitor TGR-1202

## Key facts

- **NCT ID:** NCT02874404
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-07
- **Primary completion:** 2019-07-01
- **Final completion:** 2019-07-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02874404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02874404, "TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02874404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*